PubMed Health⌕ Search

Biomedical subjects

J Oden

Publications and source records attributed to J Oden.

3 recordsLinked to original sources

Neonatal endocrinology.

Neonatal endocrinology is a diverse topic. Several chapters could be devoted to the endocrinology of fetal transition alone. The next several pages contain a brief overview of some pertinent illnesses. It is intended not to give an absolute map in the care of these patients but to help guide the physician in tailoring an approach for each patient based on current theories and practice parameters. It could also aid in improving the physician's understanding of screening laboratories used to identify those infants at risk of preventable, treatable and potentially disastrous diseases (i.e. congenial hypothyroidism). These metabolic screens are discussed due to their efficacy in the United States. In our experience, depending on the prevalence of a specific disease a few simple procedures allow for an efficient and economic way to reach ill children in a timely fashion. Other topics included in this article were reported based on their common occurrence, the lethality of illnesses if undiagnosed or their unique treatment. In the neonate hypoglycemia, either iatrogenic or secondary to sepsis, a congenital disorder of neisidioblastosis can have severe implications on the development of the CNS if not promptly treated and prevented. Some of these disorders require an experienced endocrinologist or neonatologist to treat and supervise conscientiously (i.e. CAH). However, as most of us know, it is sometimes hard to find such an individual in a community based practice. Therefore, it becomes of paramount value that each of us pays attention to the treatment of these illnesses for the sake of the children we care for.

Adrenal Hyperplasia, Congenital↗

[Malignant non-Hodgkin's lymphoma of the joint. Report of two cases, review of the literature and problems of classification].

This paper gives a survey of malignant Non-Hodgkin lymphomas (NHL) of joints. Primary and secondary malignant lymphomas of joints are rare. Our analysis of 6 years', new entries in the lymph node register in Kiel, covering 37.367 cases of malignant lymphomas, revealed only 20 cases (0.05%) with infiltration of joints. Slightly more men than women (1.18:1) are actually affected by articular lymphomas. In addition to 34 articular lymphomas of joints described in the literature between 1974 and 1992, we analyse 2 cases seen in our own institute and the 20 cases taken from the Kiel lymph node register. The peak incidence is between 40 and 60 years of age. One of our own cases, a woman of 92, is the oldest person ever affected. The most frequent localizations of NHLs are the knee, hip, and shoulder joints, with low-grade lymphomas predominating. Osteolytic lesions on radiographs are of decisive clinical and diagnostic significance for malignant articular lymphomas with affected bones. Lymphomas of joints are treated almost exclusively by radiation and chemotherapy, and sometimes a combination of both. Decisive prognostic significance attaches to the grade of malignancy and the fact of primary or secondary infiltration of the synovium and of the bone. The average survival time for patients with low-grade NHLs is 19 months with infiltration of the synovium and 27 months with infiltration of joint forming bones only, whereas the average survival time for patients high-grade lymphomas is 8 months with infiltration of the synovium and 11 months with infiltration only of joint-forming bones.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗

Refractoriness of both uterus and mammary gland of the cow to prostaglandin F2 alpha administration:P clinical application.

Uterine and mammary pressure changes were simultaneously measured in lactating nonpregnant cows injected (IV) with different doses (0.1 to 32.0 mg) of prostaglandin F2 alpha (PGF2 alpha). The total work of the uterus increased up to 250% of base-line value as the dose of PGF2 alpha was increased. But, a dose-response relationship was not seen in the uterus. Partial refractoriness was developed in the uterus, and total refractoriness was developed in the mammary gland. Further challenge with oxytocin (30 U) elicited significant responses in both the uterus and the mammary gland. Because of the development of refractoriness and side effects, PGF2 alpha is not recommended as a drug to be used when mechanical evacuation (free of endocrine effect) of the uterus or mammary gland (or both) is indicated.

Animals↗